We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · July 23, 2020

Once-Daily, Single-Inhaler Mometasone-Indacaterol-Glycopyrronium vs Mometasone-Indacaterol or Twice-Daily Fluticasone-Salmeterol for Inadequately Controlled Asthma

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Once-Daily, Single-Inhaler Mometasone-Indacaterol-Glycopyrronium Versus Mometasone-Indacaterol or Twice-Daily Fluticasone-Salmeterol in Patients With Inadequately Controlled Asthma (IRIDIUM): A Randomised, Double-Blind, Controlled Phase 3 Study
Lancet Respir Med 2020 Jul 09;[EPub Ahead of Print], HAM Kerstjens, J Maspero, KR Chapman, RN van Zyl-Smit, M Hosoe, AM Tanase, C Lavecchia, A Pethe, X Shu, P D'Andrea,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading